Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Pulmonary Fibrosis - Pipeline Review, H2 2016 - Research and Markets

Research and Markets
Posted on: 27 Oct 16

Research and Markets has announced the addition of the "Pulmonary Fibrosis - Pipeline Review, H2 2016" report to their offering.

Pulmonary Fibrosis pipeline therapeutics constitutes close to 137 molecules. Out of which approximately 125 molecules are developed by Companies and remaining by the Universities/Institutes.

Pulmonary Fibrosis - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Pulmonary Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Pulmonary Fibrosis Pulmonary fibrosis occurs when lung tissue becomes damaged and scarred. Pulmonary fibrosis can be caused by many conditions, including chronic inflammatory processes (like sarcoidosis or Wegener's granulomatosis), infections, environmental agents (asbestos, silica, exposure to certain gases), and exposure to ionizing radiation. Symptoms include shortness of breath, dry cough, fatigue and aching muscles and joints.

The molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 14, 13, 1, 84 and 12 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 9 and 3 molecules, respectively.

Furthermore, this report also reviews of key players involved in therapeutic development for Pulmonary Fibrosis and features dormant and discontinued projects.

Key Topics Covered:

  1. Introduction
  2. Pulmonary Fibrosis Overview
  3. Therapeutics Development
  4. Pipeline Products for Pulmonary Fibrosis - Overview
  5. Pipeline Products for Pulmonary Fibrosis - Comparative Analysis
  6. Pulmonary Fibrosis - Therapeutics under Development by Companies
  7. Pulmonary Fibrosis - Therapeutics under Investigation by Universities/Institutes
  8. Pulmonary Fibrosis Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Pulmonary Fibrosis - Products under Development by Companies
  13. Pulmonary Fibrosis - Products under Investigation by Universities/Institutes
  14. Pulmonary Fibrosis - Companies Involved in Therapeutics Development
  • AdAlta Pty Ltd.
  • aTyr Pharma, Inc.
  • Biogen Inc
  • Bioneer Corporation
  • BiOrion Technologies B.V.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Cynata Therapeutics Limited
  • Diffusion Pharmaceuticals Inc.
  • Digna Biotech, S.L.
  • Elsalys Biotech SAS
  • F. Hoffmann-La Roche Ltd.
  • Galectin Therapeutics, Inc.
  • GenKyoTex S.A.
  • GlaxoSmithKline Plc
  • iBio, Inc.
  • Isarna Therapeutics GmbH
  • Kadmon Corporation, LLC
  • Kasiak Research Private Limited
  • KineMed, Inc.
  • Kolltan Pharmaceuticals, Inc.
  • Kyorin Pharmaceutical Co., Ltd.
  • NicOx S.A.
  • Nitto Denko Corporation
  • Novartis AG
  • ProMetic Life Sciences Inc.
  • Pulmatrix, Inc.
  • RedHill Biopharma Ltd.
  • Respira Therapeutics Inc
  • Saje Pharma, LLC
  • Sanofi
  • Terpenoid Therapeutics, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Vericel Corporation
  • Vicore Pharma AB

For more information about this report visit

View source version on

Business Wire

Last updated on: 27/10/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.